Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Zai Lab

Evaluate

Thumbnail
June 08, 2023

Asco 2023 movers – maintaining the momentum

Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.

Thumbnail
June 07, 2023

Asco 2023 – Novocure sinks as Lunar’s limitations become clear

A pivotal lung cancer hit in an outdated setting means the company might struggle with adoption.

Article image
Vantage logo
June 03, 2023

Asco 2023 – Elevation follows in Astellas’s slipstream

There is reason for the enthusiasm behind Elevation’s anti-Claudin18.2 ADC, but no such good news for Zai Lab’s zolbetuximab challenger.

Article image
Vantage logo
April 05, 2023

Benevolent AI’s dermatology Trk disappoints

Article image
Vantage logo
January 04, 2023

US approval tracker: December 2022

Article image
Vantage logo
August 17, 2022

Abbvie leaves I-Mab out in the cold

Article image
Vantage logo
April 04, 2022

Swift resolution emerges to China's non-compliance

Article image
Vantage logo
March 11, 2022

Another strike for biotech: China

Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.

Article image
Vantage logo
January 26, 2022

Pfizer hopes Gilead’s CD47 issues aren’t catching

Article image
Vantage logo
October 04, 2021

Global pharma stocks struggle in the third quarter

A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.

Article image
Vantage logo
August 23, 2021

Trillium gets a buyout while it's down

The latest deal over a CD47 asset has got investors wondering who could be next.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up